Opus Genetics Eyes September OPGx-BEST1 Data, Extends Runway Into 2029
Opus Genetics completed enrollment in Cohort 1 of its Phase 1/2 OPGx-BEST1 trial, with three-month data due September 2026, and reported six-month OPGx-LCA5 pediatric results showing 1.5 log unit cone sensitivity gains. FDA accepted LCA5 into its Rare Disease Evidence Principles program and cash runway extends into 2029.
1. Q1 Financial and Corporate Update
Opus Genetics reported financial results for the quarter ended March 31, 2026, reaffirming a cash runway into 2029 to support multiple clinical inflection points, program advancements, and potential priority review voucher opportunities.
2. OPGx-BEST1 Phase 1/2 Enrollment and Data Timeline
Enrollment in Cohort 1 of the Phase 1/2 BIRD-1 OPGx-BEST1 trial is now complete, with both dominant and recessive BEST disease participants dosed and topline three-month data scheduled for September 2026.
3. OPGx-LCA5 Pediatric Cohort Results and FDA Acceptance
Six-month pediatric cohort data for OPGx-LCA5 demonstrated average 1.5 log unit improvements in cone sensitivity, restoring metrics to normal ranges, and the FDA granted the program acceptance into its Rare Disease Evidence Principles program.
4. Upcoming RDH12, MERTK and RHO Program Milestones
Early-stage programs include OPGx-RDH12, set to enter the clinic in Q4 2026 with RDH12 Alliance funding; OPGx-MERTK with clinical activities underway supported by Abu Dhabi’s consortium; and OPGx-RHO slated for a 2027 clinical entry following positive preclinical data.